AbbVie Inc. (ABBV) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - General

Earnings Reports

• AbbVie (ABBV) Q2 2026: Skyrizi Rises 24% as Immunology, Pipeline Depth Drive $600M Guidance Lift
  July 31, 2026
• AbbVie (ABBV) Q4 2025: Immunology Powerhouses Drive $8B+ Growth, Neuroscience and Oncology Upside Signals Multi-Year Runway
  June 15, 2026
• AbbVie (ABBV) Q1 2026: Immunology Surges 29%, Pipeline and CapEx Signal Decade-Long Growth Bet
  April 29, 2026
• AbbVie (ABBV) Q3 2025: SkyRizi and RINVOQ Surge 40% as Neuroscience Drives Diversified Growth
  October 31, 2025
• AbbVie (ABBV) Q2 2025: Ex-Humira Platform Surges 22%, Raising Full-Year Revenue Target by $1.5B
  July 31, 2025
• AbbVie (ABBV) Q1 2025: Immunology and Neuroscience Outperform as Humira Declines Sharpen
  June 10, 2025
• AbbVie (ABBV) Q3 2024: Ex-Humira Platform Grows 18% as Pipeline and Portfolio Reshape Post-LOE Trajectory
  October 30, 2024
• AbbVie (ABBV) Q2 2024: Ex-Humira Platform Delivers $6B Growth as Immunology, Neuroscience Outperform
  July 25, 2024
• AbbVie (ABBV) Q1 2024: Ex-Humira Platform Surges 15%, Offsetting Biosimilar Erosion
  April 26, 2024
• AbbVie (ABBV) Q4 2023: Ex-Humira Growth Platform Surges 15%, Powering Post-LOE Recovery
  February 02, 2024

Browse all companies